Join
Live feed
·
PRReleasevia Quantisnow
Silence Therapeutics Plc logo

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

ByQuantisnow·Wall Street's wire, on your screen.
SLN· Silence Therapeutics Plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLN (Silence Therapeutics Plc) and more on Quantisnow.